BIOFORCE NANOSCIENCES HOLDINGS, INC. — fact timeline
Source-grounded facts extracted from BIOFORCE NANOSCIENCES HOLDINGS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIOFORCE NANOSCIENCES HOLDINGS, INC. underwent a change of control involving Nexus Capital Investments, Inc. for $400,000 (closed 2026-04-15).
“April 15, 2026, Merle Ferguson (“Seller”), a current Director of the Company sold 26,700,000 shares of his common stock in the Company to Nexus Capital Investments, Inc., a Delaware Corporation (“Purchaser”). This represented Mr. Ferguson’s controlling stock interest in the Company, equalling 79.65% of the outstanding common stock of the Company. Nexus Capital Investments, Inc. paid $400,000 to the Seller from its corporate funds; no loans were involved in this transaction.”
Richard Kaiser was appointed as interim Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
“On June 17, 2026, the Company’s Board of Directors appointed Richard Kaiser as the Company’s interim Chief Executive Officer.”
Scott Mager was appointed as Director at BIOFORCE NANOSCIENCES HOLDINGS, INC..
“Effective June 15, 2026, the Board of Directors appointed Scott Mager as Directors of the Company.”
Sasha Shapiro resigned as Vice-President at BIOFORCE NANOSCIENCES HOLDINGS, INC..
“On June 17, 2026, the Company’s Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.’s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company’s Vice-President.”
John LaViolette resigned as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
“On June 17, 2026, the Company’s Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.’s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company’s Vice-President.”
Steven Gagnon resigned as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
“On June 17, 2026, the Company’s Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.’s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company’s Vice-President.”
Auditor Changes
BIOFORCE NANOSCIENCES HOLDINGS, INC. engaged Michael Gillespie & Associates, PLLC as its auditor.
“The Company has retained Michael Gillespie & Associates, PLLC as its new auditing firm.”
Auditor Changes
BIOFORCE NANOSCIENCES HOLDINGS, INC. dismissed BF Borgers CPA PC as its auditor.
“Effective May 7, 2024, BioForce NanoSciences Holdings, Inc. (the “Company) replaced BF Borgers CPA PC (“BF Borgers”) as its independent registered public accounting firm.”
Sasha Shapiro was appointed as President at BIOFORCE NANOSCIENCES HOLDINGS, INC..
“appointed Sasha Shapiro as President, effective November 30, 2021.”
John LaViolette was appointed as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
“appointed both Mr. Steve Gagnon and Mr. John LaViolette as Co-Chief Executive Officers (Co-CEOs), effective November 30, 2021.”
Steve Gagnon was appointed as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
“appointed both Mr. Steve Gagnon and Mr. John LaViolette as Co-Chief Executive Officers (Co-CEOs), effective November 30, 2021.”
Merle Ferguson resigned as Chief Executive Officer and President at BIOFORCE NANOSCIENCES HOLDINGS, INC..
“the Board of Directors accepted the resignation of Mr. Merle Ferguson as Chief Executive Officer and President, effective November 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.